Flow cytometric DNA analysis of fresh prostatic resections

Correlation with conventional prognostic parameters in patients with prostate cancer

M. H. Hussain, I. Powell, N. Zaki, Z. Maciorowski, W. Sakr, M. KuKuruga, Daniel W Visscher, G. P. Haas, J. E. Pontes, J. F. Ensley

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. DNA ploidy analysis has been investigated as a prognostic indicator in prostate cancer. Most of the data is derived from retrospective studies using paraffin-embedded tissue. This method has drawbacks related to the quality of DNA histograms and uncontrolled data collection. Methods. DNA ploidy analysis of freshly resected prostatic tissue was prospectively compared with conventional prognostic variables in 97 men treated with radical prostatectomy for localized prostate cancer. Results. Regarding the patients, 31.9% were African American and 66% had pathologic Stages C or D1 disease. Only 9.6% of patients with Stages A2 and B had a prostate-specific antigen (PSA) value greater than 10 ng/ml, whereas 97% of patients with PSA values greater than 20 ng/ml had pathologic Stages C and D1. PSA levels correlated with Gleason score (P = < 0.05); 51% and 100% of patients with Gleason score 5-7 and 8-10, respectively, had PSA values greater than 10 ng/ml. Twenty-two patients (23%) had DNA aneuploid tumors. Comparisons of mechanical to enzymatic cell suspensions indicated that DNA aneuploidy was better preserved in mechanical cell preparations. DNA ploidy correlated with pathologic stage (P = < 0.05) and Gleason score (P = < 0.05). Fifteen of 79 patients (18.9%) with Gleason score 5-7 had DNA aneuploid tumors versus 71.4% of patients with Gleason score 8-10. PSA groups correlated with ploidy status (P = 0.01). Although the majority of patients (19 of 22) with DNA aneuploid tumors had elevated preoperative PSA levels, none had a PSA value greater than 50 ng/ml. Conclusions. DNA ploidy analysis correlated with established prognostic indicators in prostate cancer; however, its independent correlation with natural history and treatment outcome must be established for it to have an effect on therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)3012-3019
Number of pages8
JournalCancer
Volume72
Issue number10
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Neoplasm Grading
Ploidies
DNA
Aneuploidy
Neoplasms
Therapeutic Uses
Prostatectomy
Natural History
varespladib methyl
African Americans
Paraffin
Suspensions
Retrospective Studies

Keywords

  • DNA ploidy
  • fresh prostatic resections
  • prostate cancer
  • prostate-specific antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Flow cytometric DNA analysis of fresh prostatic resections : Correlation with conventional prognostic parameters in patients with prostate cancer. / Hussain, M. H.; Powell, I.; Zaki, N.; Maciorowski, Z.; Sakr, W.; KuKuruga, M.; Visscher, Daniel W; Haas, G. P.; Pontes, J. E.; Ensley, J. F.

In: Cancer, Vol. 72, No. 10, 1993, p. 3012-3019.

Research output: Contribution to journalArticle

Hussain, M. H. ; Powell, I. ; Zaki, N. ; Maciorowski, Z. ; Sakr, W. ; KuKuruga, M. ; Visscher, Daniel W ; Haas, G. P. ; Pontes, J. E. ; Ensley, J. F. / Flow cytometric DNA analysis of fresh prostatic resections : Correlation with conventional prognostic parameters in patients with prostate cancer. In: Cancer. 1993 ; Vol. 72, No. 10. pp. 3012-3019.
@article{4748cd0f9c764d8db381950c5135b29b,
title = "Flow cytometric DNA analysis of fresh prostatic resections: Correlation with conventional prognostic parameters in patients with prostate cancer",
abstract = "Background. DNA ploidy analysis has been investigated as a prognostic indicator in prostate cancer. Most of the data is derived from retrospective studies using paraffin-embedded tissue. This method has drawbacks related to the quality of DNA histograms and uncontrolled data collection. Methods. DNA ploidy analysis of freshly resected prostatic tissue was prospectively compared with conventional prognostic variables in 97 men treated with radical prostatectomy for localized prostate cancer. Results. Regarding the patients, 31.9{\%} were African American and 66{\%} had pathologic Stages C or D1 disease. Only 9.6{\%} of patients with Stages A2 and B had a prostate-specific antigen (PSA) value greater than 10 ng/ml, whereas 97{\%} of patients with PSA values greater than 20 ng/ml had pathologic Stages C and D1. PSA levels correlated with Gleason score (P = < 0.05); 51{\%} and 100{\%} of patients with Gleason score 5-7 and 8-10, respectively, had PSA values greater than 10 ng/ml. Twenty-two patients (23{\%}) had DNA aneuploid tumors. Comparisons of mechanical to enzymatic cell suspensions indicated that DNA aneuploidy was better preserved in mechanical cell preparations. DNA ploidy correlated with pathologic stage (P = < 0.05) and Gleason score (P = < 0.05). Fifteen of 79 patients (18.9{\%}) with Gleason score 5-7 had DNA aneuploid tumors versus 71.4{\%} of patients with Gleason score 8-10. PSA groups correlated with ploidy status (P = 0.01). Although the majority of patients (19 of 22) with DNA aneuploid tumors had elevated preoperative PSA levels, none had a PSA value greater than 50 ng/ml. Conclusions. DNA ploidy analysis correlated with established prognostic indicators in prostate cancer; however, its independent correlation with natural history and treatment outcome must be established for it to have an effect on therapeutic decisions.",
keywords = "DNA ploidy, fresh prostatic resections, prostate cancer, prostate-specific antigen",
author = "Hussain, {M. H.} and I. Powell and N. Zaki and Z. Maciorowski and W. Sakr and M. KuKuruga and Visscher, {Daniel W} and Haas, {G. P.} and Pontes, {J. E.} and Ensley, {J. F.}",
year = "1993",
doi = "10.1002/1097-0142(19931115)72:10<3012::AID-CNCR2820721025>3.0.CO;2-Y",
language = "English (US)",
volume = "72",
pages = "3012--3019",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Flow cytometric DNA analysis of fresh prostatic resections

T2 - Correlation with conventional prognostic parameters in patients with prostate cancer

AU - Hussain, M. H.

AU - Powell, I.

AU - Zaki, N.

AU - Maciorowski, Z.

AU - Sakr, W.

AU - KuKuruga, M.

AU - Visscher, Daniel W

AU - Haas, G. P.

AU - Pontes, J. E.

AU - Ensley, J. F.

PY - 1993

Y1 - 1993

N2 - Background. DNA ploidy analysis has been investigated as a prognostic indicator in prostate cancer. Most of the data is derived from retrospective studies using paraffin-embedded tissue. This method has drawbacks related to the quality of DNA histograms and uncontrolled data collection. Methods. DNA ploidy analysis of freshly resected prostatic tissue was prospectively compared with conventional prognostic variables in 97 men treated with radical prostatectomy for localized prostate cancer. Results. Regarding the patients, 31.9% were African American and 66% had pathologic Stages C or D1 disease. Only 9.6% of patients with Stages A2 and B had a prostate-specific antigen (PSA) value greater than 10 ng/ml, whereas 97% of patients with PSA values greater than 20 ng/ml had pathologic Stages C and D1. PSA levels correlated with Gleason score (P = < 0.05); 51% and 100% of patients with Gleason score 5-7 and 8-10, respectively, had PSA values greater than 10 ng/ml. Twenty-two patients (23%) had DNA aneuploid tumors. Comparisons of mechanical to enzymatic cell suspensions indicated that DNA aneuploidy was better preserved in mechanical cell preparations. DNA ploidy correlated with pathologic stage (P = < 0.05) and Gleason score (P = < 0.05). Fifteen of 79 patients (18.9%) with Gleason score 5-7 had DNA aneuploid tumors versus 71.4% of patients with Gleason score 8-10. PSA groups correlated with ploidy status (P = 0.01). Although the majority of patients (19 of 22) with DNA aneuploid tumors had elevated preoperative PSA levels, none had a PSA value greater than 50 ng/ml. Conclusions. DNA ploidy analysis correlated with established prognostic indicators in prostate cancer; however, its independent correlation with natural history and treatment outcome must be established for it to have an effect on therapeutic decisions.

AB - Background. DNA ploidy analysis has been investigated as a prognostic indicator in prostate cancer. Most of the data is derived from retrospective studies using paraffin-embedded tissue. This method has drawbacks related to the quality of DNA histograms and uncontrolled data collection. Methods. DNA ploidy analysis of freshly resected prostatic tissue was prospectively compared with conventional prognostic variables in 97 men treated with radical prostatectomy for localized prostate cancer. Results. Regarding the patients, 31.9% were African American and 66% had pathologic Stages C or D1 disease. Only 9.6% of patients with Stages A2 and B had a prostate-specific antigen (PSA) value greater than 10 ng/ml, whereas 97% of patients with PSA values greater than 20 ng/ml had pathologic Stages C and D1. PSA levels correlated with Gleason score (P = < 0.05); 51% and 100% of patients with Gleason score 5-7 and 8-10, respectively, had PSA values greater than 10 ng/ml. Twenty-two patients (23%) had DNA aneuploid tumors. Comparisons of mechanical to enzymatic cell suspensions indicated that DNA aneuploidy was better preserved in mechanical cell preparations. DNA ploidy correlated with pathologic stage (P = < 0.05) and Gleason score (P = < 0.05). Fifteen of 79 patients (18.9%) with Gleason score 5-7 had DNA aneuploid tumors versus 71.4% of patients with Gleason score 8-10. PSA groups correlated with ploidy status (P = 0.01). Although the majority of patients (19 of 22) with DNA aneuploid tumors had elevated preoperative PSA levels, none had a PSA value greater than 50 ng/ml. Conclusions. DNA ploidy analysis correlated with established prognostic indicators in prostate cancer; however, its independent correlation with natural history and treatment outcome must be established for it to have an effect on therapeutic decisions.

KW - DNA ploidy

KW - fresh prostatic resections

KW - prostate cancer

KW - prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=0027361187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027361187&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19931115)72:10<3012::AID-CNCR2820721025>3.0.CO;2-Y

DO - 10.1002/1097-0142(19931115)72:10<3012::AID-CNCR2820721025>3.0.CO;2-Y

M3 - Article

VL - 72

SP - 3012

EP - 3019

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -